InspireMD, Inc. (NASDAQ:NSPR) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Chuck Padala - IR, LifeSci Advisors Marvin Slosman - CEO Craig Shore - CFO Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Good morning, and welcome to the InspireMD Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to Chuck Padala with LifeSci Advisors. Thank ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2123838 (State or other jurisdiction of incorporation or organization) 4 Menor ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2022 was $1.431 million, an increase of 33.6% compared to $1.071 million in Q3 2021 [22] - CGuard revenue grew by nearly 39% year-over-year, reaching over $1.4 million [7] - Gross profit increased to $366,000 in Q3 2022 from $92,000 in Q3 2021, representing an increase of almost 300% [23] - Gross margin improved to 25.6% in Q3 2022 from 8.6% in Q3 2021 [23] - Net loss for Q3 2022 was $4.529 million, or $0.58 per share, compared to a net loss of $4.071 million, or $0.53 per share, in the same period in 2021 [25] Business Line Data and Key Metrics Changes - The company sold 2,624 CGuard stent systems in Q3 2022, a growth of 54% year-over-year compared to 1,709 units sold in Q3 2021 [7] - The increase in sales was driven by growth in existing markets and U.S. sales related to the C-Guardians FDA clinical trial [22] Market Data and Key Metrics Changes - The company enjoys greater than 20% market share in approximately half of its markets, with some territories exceeding 80% [8] - The regulatory landscape in Europe is undergoing significant changes with new compliance regulations under the MDR certification for CE Mark [11] Company Strategy and Development Direction - The company is focused on dominating the carotid revascularization space with the CGuard stent system and plans to launch new delivery systems to enhance market share [9][19] - A strategic partnership with NAMSA has been established to accelerate new product development and commercialization [16] - The company aims to change the paradigm of carotid stenosis management with its CGuard EPS stent platform [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the enrollment progress for the C-Guardians trial, expecting completion by Q1 2023 [28] - The company is closely monitoring the regulatory compliance process in Europe and is prioritizing inventory management to mitigate potential delays [31][33] - Management remains optimistic about the growth potential in Asia, particularly Japan, where discussions with potential distributor partners are ongoing [18] Other Important Information - The CGuard Optima study was presented at the 2022 TCT conference, highlighting the device's performance in preventing carotid artery-related complications [13][14] - The company is developing two new delivery systems to enhance the utilization of CGuard across the vascular specialist community [19] Q&A Session Summary Question: Status of enrollment for C-Guardians trial - Management confirmed that enrollment is progressing well, with expectations to complete by the end of Q1 2023 [28] Question: Update on CREST-2 trial - Management noted that the process of finalizing contracts with sites has been slower than anticipated, but they expect progress as more sites are added [30] Question: CE Mark certification timeline - Management indicated that estimating the timeline for CE Mark certification is challenging due to regulatory complexities, but they are working closely with their notified body [31][32] Question: Impact of currency fluctuations on ASPs and market share - Management acknowledged the impact of currency fluctuations but confirmed that local currency ASPs have increased mid-single digits, with market share gains in several regions [34][36] Question: Terms of potential partnership in Japan - Management discussed considerations for distributor partnerships in Japan, including regulatory paths, distributor capabilities, and potential investment structures [38]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Emplo ...

Financial Data and Key Metrics Changes - Revenue for Q2 2022 totaled $1.5 million, representing a growth of nearly 48% compared to Q2 2021 [7] - Gross profit increased to $431,000 in Q2 2022 from $262,000 in Q2 2021, with gross margin rising to 28.1% from 25.2% [28][30] - Net loss for Q2 2022 was $4.636 million or $0.59 per share, compared to a net loss of $3.507 million or $0.46 per share in Q2 2021 [31] Business Line Data and Key Metrics Changes - Sales volume of CGuard EPS increased by 47.8% to $1.505 million in Q2 2022 from $1.019 million in Q2 2021, driven by growth in existing and new markets [27][28] - The volume of units sold increased by 60%, with 2,602 units sold in Q2 2022 compared to 1,623 in Q2 2021 [8] Market Data and Key Metrics Changes - Market share growth is now greater than 20% in over half of the markets, with some territories reaching up to 60% [10][39] - The company is focusing on converting open surgeries to endovascular treatments, as less than 35% of carotid artery disease cases are currently treated through endovascular stenting procedures [12][13] Company Strategy and Development Direction - The strategy focuses on converting open surgery to endovascular procedures and promoting CGuard as a first-line endovascular device [14] - The company is expanding its direct sales model, currently active in the UK and France, with plans to extend to additional territories [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing transition from open surgery to endovascular standard of care, highlighting the significant potential for market penetration [12][19] - The company is optimistic about the enrollment completion for the U.S. IDE trial, C-Guardians, expected by Q1 2023 [20] Other Important Information - The company has a significant presence at medical conferences, which aids in demonstrating CGuard and influencing market demand [15] - Discussions with potential distribution partners in Japan are ongoing, indicating a high level of interest in the CGuard product [21] Q&A Session Summary Question: Comments on Q2 numbers and ASP decline - Management noted that the ASP decline was predominantly due to currency exchange impacts, with a 12% effect, while unit sales grew by 60% [34][35] Question: Market share growth statistics - Market share is calculated based on carotid artery stenting (CAS) procedures, with over 20% share in more than 50% of markets and up to 60% in some [37][38] Question: Competitor's regulatory clearance and market opportunity - Management acknowledged the ongoing need for TCAR as an alternative delivery option in Europe and expressed excitement about serving that market [40][41] Question: Update on CGuard Prime and Switchguard development - Development efforts for CGuard Prime and Switchguard are on track, currently in the regulatory approval phase [43] Question: Enrollment status for CREST-2 trial - Management indicated that they do not have a firm number on patient enrollment but are optimistic about making CGuard available to the 20 sites involved [44][45]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 (State or other jurisdiction of (I.R.S. Employer i ...

InspireMD, Inc. (NASDAQ:NSPR) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Chuck Padala - Investor Relations Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings and welcome to InspireMD First Quarter 2022 Earnings Call. [Operator Instructions] At this time, I???d like to turn the call over to your host, Chuck Padala, LifeSci Advisors. Thank you. You may begin. Chu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission file number: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Delaware 26-2123838 4 Menorat Hamaor St. ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO S ...

InspireMD, Inc. (NASDAQ:NSPR) Q4 2021 Earnings Conference Call March 8, 2022 8:30 AM ET Company Participants Chuck Padala - Managing Director, LifeSci Advisors Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Operator Greetings, and welcome to InspireMD Fourth Quarter and Full-Year 2021 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2123838 (State or other jurisdiction of incorporation or organization) 4 Menor ...